TACE联合微波消融术治疗不可切除孤立性肝癌的安全性及疗效研究

Study on the Safety and Efficacy of TACE Combined with Microwave Ablation in the Treatment of Unresectable Solitary Liver Cancer

目的探索TACE联合微波消融术治疗不可切除孤立性肝癌的安全性及疗效。方法选择65例不可切除孤立性肝癌患者为试验对象,根据随机数字表法分2组,观察组32例采用TACE联合微波消融术治疗,对照组33例采用TACE联合射频消融术治疗,并比较两组免疫功能、疾病控制率,同时随访12个月,计算生存时间和生存率。结果观察组治疗后12周的CD4^(+)/CD8^(+)(1.78±0.45)、CD8^(+)(24.12±2.11)%、CD4^(+)(43.68±3.26)%、CD3^(+)(67.82±4.49)%改善情况优于对照组(P<0.05),治疗后4周的疾病缓解率50.00%、治疗后8周的疾病缓解率71.88%、治疗后12周的疾病缓解率93.75%,均高于对照组(P<0.05)。经随访12个月,观察组生存率93.75%高于对照组(P<0.05),生存时间(10.37±0.44)个月长于对照组(P<0.05)。结论对不可切除孤立性肝癌患者实施TACE联合微波消融术治疗,可提高疾病控制率,延长生存时间。

Objective To explore the safety and efficacy of TACE combined with microwave ablation in the treatment of unresectable solitary liver cancer.Methods 65 patients with unresectable solitary liver cancer were selected as experimental subjects and divided into 2 groups according to the random number table method.32 cases in the observation group were treated with TACE combined with microwave ablation,and 33 cases in the control group were treated with TACE combined with radiofrequency ablation,and compared The immune function and disease control rate of the two groups were followed up for 12 months at the same time to calculate the survival time and survival rate.Results The improvement of CD4^(+)/CD8^(+)(1.78±0.45),CD8^(+)(24.12±2.11)%,CD4^(+)(43.68±3.26)%,and CD3^(+)(67.82±4.49)% of the observation group at 12 weeks after treatment was better than that of the control group(P<0.05),the disease remission rate at 4 weeks after treatment was 50.00%,the disease remission rate at 8 weeks after treatment was 71.88%,and the disease remission rate at 12 weeks after treatment was 93.75%,which were higher than those of the control group(P<0.05).After 12 months of follow-up,the survival rate of the observation group was 93.75% higher than that of the control group(P<0.05),and the survival time(10.37±0.44)months was longer than that of the control group(P<0.05).Conclusion TACE combined with microwave ablation for patients with unresectable solitary liver cancer can improve disease control rate and prolong survival time.